Bristol Myers Squibb Co – ‘NT 10-Q’ for 9/30/02

On:  Friday, 11/15/02, at 2:26pm ET   ·   Effective:  11/15/02   ·   For:  9/30/02   ·   Accession #:  950157-2-763   ·   File #:  1-01136

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Notice of a Late Filing of a Form 10-Q   —   Form 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 10-Q     Notification of Late Filing                            3     16K 

NT 10-Q
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  

FORM 12b-25 

NOTIFICATION OF LATE FILING 

                                                     SEC File Number: 1-1136

(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q            
[ ] Form N-SAR                                        

For Period Ended:   September 30, 2002                                          

[ ] Transition Report on Form 10-K                                              
[ ] Transition Report on Form 20-F                                              
[ ] Transition Report on Form 11-K                                              
[ ] Transition Report on Form 10-Q                                              
[ ] Transition Report on Form N-SAR                                             
For the Transition Period Ended: ___________                                    

  Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.                                      

If the notification relates to a portion of the filing checked above, 
identify the Item(s) to which the notification relates:                         

PART I - REGISTRANT INFORMATION                                           

Bristol-Myers Squibb Company                                              
  ----------------------------------------------------------------------------
Full Name of Registrant                                                   

Not applicable                                                            
  ----------------------------------------------------------------------------
Former Name if Applicable                                                 

345 Park Avenue                                                           
  ----------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)                 

New York, N.Y. 10154                                                      
  ----------------------------------------------------------------------------
City, State and Zip Code                                                  

PART II - RULES 12b-25(b) AND (c)                                     

If the subject report could not be filed without unreasonable effort or   
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the         
following should be completed. (Check box if appropriate.) [ ]                  

 (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;                 

 (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on  
or before the fifteenth calendar day following the prescribed due date; or the  
subject quarterly report or transition report on Form 10-Q, or portion thereof  

NT 10-Q
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
                                                                           2

will be filed on or before the fifth calendar day following the prescribed due  
date; and                                                                       

(c) The accountant's statement or other exhibit required by Rule      
12b-25(c) has been attached if applicable.                                      

PART III - NARRATIVE                                                  

  State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, N-SAR, or the transition report or portion thereof, could not be filed    
within the prescribed time period.                                              

  On October 24, 2002, Bristol-Myers Squibb Company (the "Company") issued
a press release, which was subsequently filed with the Securities and Exchange  
Commission (the "SEC") on the Company's Current Report on Form 8-K, announcing  
that it expects to restate sales and earnings for the prior periods that were   
affected by the Company's previously disclosed U.S. wholesaler inventory        
buildup situation. The Company previously announced that there will be a delay  
in filing the Company's Quarterly Report on Form 10-Q for the quarterly period  
ended September 30, 2002 ("Third Quarter 2002 Form 10-Q"), and an amendment of  
the Company's earlier filings, due to the expected restatement of the           
Company's sales and earnings. The Company is currently working with its         
independent auditors, PricewaterhouseCoopers LLP, on the complex task of        
completing the restatement. As a result of the restatement, the Company has     
not completed its review of quarterly results for the period ended September    
30, 2002, and PricewaterhouseCoopers LLP has not completed a review of interim  
financial statements to be included in the Third Quarter 2002 Form 10-Q in      
accordance with professional standards and procedures for conducting such       
reviews, as established by generally accepted auditing standards, as may be     
modified or supplemented by the SEC. Accordingly, the Company is unable to      
complete its Third Quarter 2002 Form 10-Q within the prescribed time period.    
As reported on the Company's Current Report on Form 8-K filed with the SEC on   
November 15, 2002, the Company expects to file its Third Quarter 2002 Form      
10-Q in February 2003.                                                          

PART IV - OTHER INFORMATION                                           

(1) Name and telephone number of person to contact in regard to this      
notification                                                                    

Sandra Leung                                                    
--------------------                                                    
(Name)                                                      

(212)                                   546-4000          
---------------------                     ------------------            
(Area Code)                           (Telephone Number)        

   (2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company     
Act of 1940 during the preceding 12 months or for such shorter period that the  
registrant was required to file such report(s) been filed? If answer is no,     
identify report(s). [X] Yes [ ] No                                              

(3) Is it anticipated that any significant change in results of       
operations from the corresponding period for the last fiscal year will be       
reflected by the earnings statements to be included in the subject report or    
portion thereof? [X] Yes [_] No                                                 

NT 10-Q
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
                                                                           3

  If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable     
estimate of the results cannot be made.                                         

   As disclosed in the Company's October 24, 2002 press release, the Company
expects to restate sales and earnings upward for 2002 and downward for prior    
periods that were affected, primarily in 2000 and 2001, by the Company's        
previously disclosed wholesaler inventory buildup situation in its U.S.         
pharmaceuticals unit. The Company is currently working on completing the        
restatement, including determining the impact of the restatement on the         
relevant quarterly periods, and has not completed its review of quarterly       
results for the period ended September 30, 2002. Accordingly, the Company is    
unable to quantify and discuss for the quarterly period ended September 30,     
2002 any significant changes of operations from the corresponding prior         
period.                                                                         

Bristol-Myers Squibb Company  
--------------------------------------------  
(Name of Registrant as Specified in Charter)  

has caused this notification to be signed on its behalf by the undersigned      
hereunto duly authorized.                                                       

Date   November 15, 2002                         By /s/ Sandra Leung            
-----------------                            -------------------- 
                                           Name:  Sandra Leung
                                        Title: Secretary

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘NT 10-Q’ Filing		Date		First		Last			Other Filings
Filed on / Effective on:		11/15/02		2		3			8-K
		10/24/02		2		3			8-K
For Period End:		9/30/02		1		3			10-Q
									List all Filings